Putrescine-modified nerve growth factor: Bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution

Journal of Neurochemistry

Volumn 71, Issue 4, 1998, Pages 1651-1660

  Poduslo, Joseph F ^a   Curran, Geoffry L ^a   Gill, Jagjit S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Blood brain nerve barriers; Nerve growth factor; Protein delivery

Indexed keywords

ANTIOXIDANT; NERVE GROWTH FACTOR; NEUROTROPHIN; POLYAMINE; PUTRESCINE; SPERMIDINE; SPERMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; GENE TARGETING; INTRAVENOUS DRUG ADMINISTRATION; ISOELECTRIC FOCUSING; MALE; MOLECULAR MIMICRY; MOUSE; NERVE CELL CULTURE; NERVE FIBER GROWTH; NERVOUS SYSTEM; NONHUMAN; PH; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN MODIFICATION; RAT; SPINAL GANGLION;

ANIMALIA;

EID: 0031663779     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1998.71041651.x     Document Type: Article

References (34)

1. Drinkwater C. C., Barker P. A., Suter U., and Shooter E. M. (1993) The carboxyl terminus of nerve growth factor is required for biological activity. J. Biol. Chem. 268, 23202-23207.
2. Estennebouhtou G., Kullander K., Karlsson M., Ebendal T., Hacksell U., and Luthman K. (1996) Design, synthesis, tandem mass spectrometric sequencing and biological activity of NGF mimetics. Int. J. Pept. Protein Res. 48, 337-346.
3. Hallbook F., Ibanez C. F., and Persson H. (1991) Evolutionary studies of the nerve growth factor family reveal a novel member abundantly expressed in Xenopus ovary. Neuron 6, 845-858.
4. Holland D. R., Cousens L. S., Meng W., and Matthews B. W. (1994) Nerve growth factor in different crystal forms displays structural flexibility and reveals zinc binding sites. J. Mol. Biol. 239, 385-400.
5. Ibanez C. F. (1994) Structure-function relationships in the neurotrophin family. J. Neurobiol. 25, 1349-1361.
6. Ibanez C. F. (1995) Neurotrophic factors: from structure-function studies to designing effective therapeutics. Tibtech 13, 217-227.
7. Ibanez C. F., Hallbook F., Soderstrom S., Ebendal T., and Persson H. (1991) Biological and immunological properties of recombinant human, rat, and chicken nerve growth factors - a comparative study. J. Neurochem. 57, 1033-1041.
8. Ibanez C. F., Ilag L. L., Murray-Rust J., and Persson H. (1993) An extended surface of binding to trk tyrosine kinase receptors in NGF and BDNF allows the engineering of a multifunctional pan-neurotrophin. EMBO J. 12, 2281-2293.
9. Ilag L. L., Lonnerberg P., Persson H., and Ibanez C. F. (1994) Role of variable β-hairpin loop in determining biological specificities in neurotrophin family. J. Biol. Chem. 269, 19941-19946.
10. trkA. J. Biol. Chem. 267, 22707-22710.
11. Kullander K. and Ebendal T. (1994) Neurotrophin-3 acquires NGF-like activity after exchange to five NGF amino acid residues: molecular analysis of the sites in NGF mediating the specific interaction with the NGF high affinity receptor. J. Neurosci. Res. 39, 195-210.
12. Lesauteur L., Wei L., Gibbs B. F., and Saragovi H. U. (1995) Small peptide mimics of nerve growth factor bind trka receptors and affect biological responses. J. Biol. Chem. 270, 6564-6569.
13. Longo F. M., Vu T., and Mobley W. C. (1990) The in vitro biological effect of nerve growth factor is inhibited by synthetic peptides. Cell Regul. 1, 189-195.
14. Luo Y. and Neet K. E. (1992) The unprocessed C-termmal dipeptide of recombinant β-nerve growth factor determines three stable forms with distinct biological activities. J. Biol. Chem. 267, 12275-12283.
15. McDonald N. Q., Lapatto R., Murray-Rust J., Gunning J., Wlodawer A., and Blundell T. L. (1991) New protein fold revealed by a 2.3-Å resolution crystal structure of NGF. Nature 354, 411-414.
16. Murphy R. A., Acheson A., Hodges R., Haskins J., Richards C., Reklow E., Chlumecky V., Barker P. A., Alderson R. F., and Lindsay R. M. (1993) Immunological relationships of NGF, BDNF, and NT-3: recognition and functional inhibition by antibodies to NGF. J. Neurosci. 13, 2853-2862.
17. trk (Trk) receptor binding. J. Neurosci. Res. 37, 433-444.
18. Poduslo J. F. (1981) Glycoprotein molecular weight estimation using SDS-pore gradient electrophoresis: comparison of TRIS-glycine and TRIS-borate-EDTA buffer systems. Anal. Biochem. 114, 131-139.
19. 0 occurs in the presence of myelin assembly but not in its absence. J. Biol. Chem. 265, 3719-3725.
20. Poduslo J. F. (1993) Albumin and the blood-nerve barrier, in Peripheral Neuropathy (Dyck P. J., Thomas P. K., Griffin J. W., Low P. A., and Poduslo J. F., eds), pp. 446-452. W. B. Saunders, Philadelphia.
21. Poduslo J. F. and Curran G. L. (1992) Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc. Natl. Acad. Sci. USA 89, 2218-2222.
22. Poduslo J. F. and Curran G. L. (1994) Glycation increases in permeability of proteins across the blood-nerve and blood-brain barriers. Mol. Brain Res. 23, 157-162.
23. Poduslo J. F. and Curran G. L. (1996a) Permeability at the blood-brain and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Mol. Brain Res. 36, 280-286.
24. Poduslo J. F. and Curran G. L. (1996b) Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J. Neurochem. 66, 1599-1609.
25. Poduslo J. F. and Curran G. L. (1996c) Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine. J. Neurochem. 67, 734-741.
26. Poduslo J. F., Low P. A., Windebank A. J., Dyck P. J., Berg C. T., and Schmelzer J. D. (1982) Altered blood nerve barrier in experimental lead neuropathy assessed by changes in endoneurial albumin concentration. J. Neurosci. 2, 1507-1514.
27. Poduslo J. F., Curran G. L., and Dyck P. J. (1988) Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy. Proc. Natl. Acad. Sci. USA 85, 4879-4883.
28. Poduslo J. F., Curran G. L., and Berg C. T. (1994) Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. USA 91, 5705-5709.
29. Shih A., Laramee G. R., Schmelzer C. H., Burton L. E., and Winslow J. W. (1994) Mutagenesis identifies amino-terminal residues of nerve growth factor necessary for Trk receptor binding and biological activity. J. Biol. Chem. 269, 27679-27686.
30. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., and Klenk D. C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
31. Wengenack T. M., Curran G. L., Olson E. E., and Poduslo J. F. (1997a) Putrescine-modified catalase with preserved enzymatic activity exhibits increased permeability at the blood-nerve and blood-brain barriers. Brain Res. 767, 128-135.
32. Wengenack T. M., Curran G. L., and Poduslo J. F. (1997b) Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia. Brain Res. 754, 46-54.
33. Woo S. B. and Neet K. E. (1996) Characterization of histidine residues essential for receptor binding and activity of nerve growth factor. J. Biol. Chem. 271, 24433-24441.
34. 2-terminal residues of nerve growth factor affects activity and Trk binding without affecting stability or conformation. J. Biol. Chem. 270, 6278-6285.